Current Edition


FDA, as expected, rejects Lilly and Innovent immunotherapy in signal to drugmakers

Dive Brief: The Food and Drug Administration has rejected an experimental cancer immunotherapy Eli Lilly and partner Innovent Biologics have been developing for a common …

Continue Reading →

Biohaven’s pipeline takes a hit as drug for rare neurological disease falls short in trial

Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales …

Continue Reading →

US stocks up on COVID-19 antibody drugs amid shortage concerns

The antibody treatments from Regeneron and Eli Lilly have been proven effective in reducing the risk of hospitalization or death from COVID-19 in certain high-risk …

Continue Reading →

AstraZeneca wins first FDA approval for systemic lupus drug in a decade

Benlysta’s approval was itself a landmark, being the first such drug approved in decades. Its use has grown slowly and steadily over time, falling just …

Continue Reading →